Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer

[1] Freifeld AG(2011)Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America Clin Infect Dis 52 56-93

[2] Bow EJ(2004)Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228-237

[3] Sepkowitz KA(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors Eur J Cancer 47 8-32

[4] Boeckh MJ(2006)2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205

[5] Ito JI(2007)Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 1705-1715

[6] Mullen CA(2007)Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 1695-1704

[7] Raad II(2006)Adjuvant docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck Anticancer Res 26 559-563

[8] Rolston KV(2007)Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest oncology group phase II study Cancer Invest 25 182-188

[9] Young JA(2004)Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary Clin Infect Dis 39 S49-52

[10] Wingard JR(1992)Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American College of Chest Physicians/Society of Critical Care Medicine Chest 101 1644-1655

[1] Freifeld AG(2011)Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America Clin Infect Dis 52 56-93

[2] Bow EJ(2004)Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228-237

[3] Sepkowitz KA(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors Eur J Cancer 47 8-32

[4] Boeckh MJ(2006)2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205

[5] Ito JI(2007)Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 1705-1715

[6] Mullen CA(2007)Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 1695-1704

[7] Raad II(2006)Adjuvant docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck Anticancer Res 26 559-563

[8] Rolston KV(2007)Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest oncology group phase II study Cancer Invest 25 182-188

[9] Young JA(2004)Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary Clin Infect Dis 39 S49-52

[10] Wingard JR(1992)Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American College of Chest Physicians/Society of Critical Care Medicine Chest 101 1644-1655